Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of United Therapeutics Corporation. A complete text table follows the diagram.
Treprostinil therapies produce 92% of revenue while the company engineers gene-edited kidneys, hearts, lungs and liver alternatives
Swipe to explore
Every product leaf is an exact reported revenue amount. The $719.7 million treprostinil platform parent is the arithmetic sum of Tyvaso DPI, Nebulized Tyvaso, Remodulin and Orenitram; the $61.8 million other-therapies parent is the sum of the remaining reported categories.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| United Therapeutics revenue | 1 | $782M | Rare-disease medicines funding organ engineering |
| Treprostinil platform | 2 | $720M | 92% of company revenue |
| Other therapies & services | 2 | $61.8M | Oncology, tadalafil and lung services |
| Tyvaso DPI | 3 | $330M | Portable dry-powder inhaler |
| Nebulized Tyvaso | 3 | $127M | Inhaled solution with IPF expansion path |
| Remodulin | 3 | $127M | Continuous infused treprostinil |
| Orenitram | 3 | $136M | Oral extended-release treprostinil |
| Unituxin | 3 | $53.6M | Pediatric neuroblastoma antibody |
| Adcirca | 3 | $2.9M | PAH tadalafil facing generics |
| Other revenue | 3 | $5.3M | Includes ex vivo lung perfusion |
| From | To | Value |
|---|---|---|
| United Therapeutics revenue | Treprostinil platform | $720M |
| United Therapeutics revenue | Other therapies & services | $61.8M |
| Treprostinil platform | Tyvaso DPI | $330M |
| Treprostinil platform | Nebulized Tyvaso | $127M |
| Treprostinil platform | Remodulin | $127M |
| Treprostinil platform | Orenitram | $136M |
| Other therapies & services | Unituxin | $53.6M |
| Other therapies & services | Adcirca | $2.9M |
| Other therapies & services | Other revenue | $5.3M |